<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02077335</url>
  </required_header>
  <id_info>
    <org_study_id>CSSSG-001</org_study_id>
    <nct_id>NCT02077335</nct_id>
  </id_info>
  <brief_title>Study of High-dose Rate (HDR) Monotherapy for Low and Intermediate Risk Prostate Cancer</brief_title>
  <official_title>Phase II Study of High-dose Rate (HDR) Monotherapy for the Treatment of Low and Intermediate Risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSSS de Gatineau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSSS de Gatineau</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the clinical efficacy and toxicity of High-dose
      rate (HDR) brachytherapy as monotherapy for the treatment of low risk and intermediate risk
      prostate cancer.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Disease free survival as evaluated by absence of biochemical recurrence (Phoenix criteria) and absence of clinically/radiologically diagnosed local, regional or distant recurrence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Genito-urinary (GU) toxicity</measure>
    <time_frame>6 weeks, 2 years and 5 years post treatment</time_frame>
    <description>Toxicity according to International prostate symptom score (IPSS) and Expanded Prostate Index Composite (EPIC) questionnaires.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Gastro-Intestinal (GI) Toxicity</measure>
    <time_frame>6 weeks, 2 years and 5 years post treatment</time_frame>
    <description>Toxicity according to Expanded Prostate Index Composite (EPIC) questionnaires.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>HDR brachytherapy monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation therapy: Treatment with 2 separate HDR brachytherapy implants, each with one fraction of 13.5 Gray (Gy) with an interval of 7-14 days between treatments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>HDR brachytherapy monotherapy</intervention_name>
    <description>Radiation therapy in the study consists of treatment with 2 separate interstitial HDR brachytherapy procedures with temporary interstitial catheters, each with one fraction of 13.5 Gray (Gy). Both procedures will be done in an identical manner. The 2 procedures will be separated by an interval of 7-14 days Treatments will be done with interstitial catheters inserted transperineally with transrectal ultrasound guidance under sterile conditions. Optimization of treatment plan will be done with Brachyvision software (Varian, Palo Alto CA) based on CT-scan imaging done post-implant. Optimization parameters will be the following:
Prostate :
V100 &gt; 95%
V150 30-35%
V200 &lt; 15%
D90 &gt; 90% (12,15Gy)
Bladder
• V75 &lt; 1cc
Rectum
• V75 &lt; 1cc
Urethra
V125 = 0cc D10 &lt; 120%
Treatments will be carried out with an Iridium-192 afterloader. Source and all catheters will be removed from the patient at the end of the procedure.</description>
    <arm_group_label>HDR brachytherapy monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven Adenocarcinoma of the Prostate

          -  Clinical stage T1c, T2a or T2b

          -  PSA less than 20 ng/ml

          -  Gleason Score 6 or 7

        Exclusion Criteria:

          -  Age less than 18 years

          -  Clinical stage T2c, T3 ou T4

          -  Clinical Stage N1

          -  Clinical Stage M1

          -  Prostate Specific Antigen (PSA) more than 20 ng/ml

          -  Gleason score 8 or higher

          -  IPSS score 19 or higher with alpha-blockers

          -  Past radiation therapy to the pelvis

          -  History of Collagen Vascular Disease

          -  History of Inflammatory Bowel Disease

          -  Bilateral Hip Prosthesis
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CSSS de Gatineau</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8P 7H2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2014</study_first_submitted>
  <study_first_submitted_qc>March 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2014</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CSSS de Gatineau</investigator_affiliation>
    <investigator_full_name>Marc Gaudet</investigator_full_name>
    <investigator_title>Radiation Oncologist</investigator_title>
  </responsible_party>
  <keyword>Brachytherapy</keyword>
  <keyword>Monotherapy</keyword>
  <keyword>HDR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

